Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds.
A hairless mouse-herpes simplex virus skin infection experimental model was used to evaluate the efficacy of the antiviral compounds 9-beta-d-arabinofuranosyladenine (ara-A), 5-iodo-2'-deoxyuridine (IUdR), and 6-azauridine (aza-U). Ara-A and IUdR, when administered intraperitoneally by several different dosage schedules, reduced the severity of cutaneous herpetic lesions and the incidence of paralysis and increased significantly the number of survivors. A more rapid healing of the lesions and an increase in the mean survival time also was observed. A delay of 24 to 48 h in the initiation of treatment after the infection was more effective than treatments started at the time of inoculation. Treatment with ara-A was somewhat superior to that with IUdR, but aza-U was totally ineffective. Enhancement of the evolution of the infection was noted after treatment with aza-U.
D000225:Adenine / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001089:Arabinose / Q000627:therapeutic use; D001380:Azauridine / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy*; D008297:Male; D009705:Nucleosides / Q000627:therapeutic use; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use
D000998:Antiviral Agents; D009705:Nucleosides; D014498:Uracil; D001380:Azauridine; D001089:Arabinose; D000225:Adenine